Header

UZH-Logo

Maintenance Infos

HSV-1 amplicon vectors launch the production of heterologous Rotavirus-like particles and induce Rotavirus-specific immune responses in mice


Laimbacher, Andrea S; Esteban, Laura E; Castello, Alejandro A; Abdusetir Cerfoglio, Juan C; Argüelles, Marcelo H; Glikmann, Graciela; D'Antuono, Alejandra; Mattion, Nora; Berois, Mabel; Arbiza, Juan; Hilbe, Monika; Schraner, Elisabeth M; Seyffert, Michael; Dresch, Christiane; Epstein, Alberto L; Ackermann, Mathias; Fraefel, Cornel (2012). HSV-1 amplicon vectors launch the production of heterologous Rotavirus-like particles and induce Rotavirus-specific immune responses in mice. Molecular Therapy, 20(9):1810-1820.

Abstract

Virus-like particles (VLPs) are promising vaccine candidates because they represent viral antigens in the authentic conformation of the virion and are therefore readily recognized by the immune system. As VLPs do not contain genetic material they are safer than attenuated virus vaccines. In this study, herpes simplex virus type 1 (HSV-1) amplicon vectors were constructed to coexpress the rotavirus (RV) structural genes VP2, VP6, and VP7 and were used as platforms to launch the production of RV-like particles (RVLPs) in vector-infected mammalian cells. Despite the observed splicing of VP6 RNA, full-length VP6 protein and RVLPs were efficiently produced. Intramuscular injection of mice with the amplicon vectors as a two-dose regimen without adjuvants resulted in RV-specific humoral immune responses and, most importantly, immunized mice were partially protected at the mucosal level from challenge with live wild-type (wt) RV. This work provides proof of principle for the application of HSV-1 amplicon vectors that mediate the efficient production of heterologous VLPs as genetic vaccines.

Abstract

Virus-like particles (VLPs) are promising vaccine candidates because they represent viral antigens in the authentic conformation of the virion and are therefore readily recognized by the immune system. As VLPs do not contain genetic material they are safer than attenuated virus vaccines. In this study, herpes simplex virus type 1 (HSV-1) amplicon vectors were constructed to coexpress the rotavirus (RV) structural genes VP2, VP6, and VP7 and were used as platforms to launch the production of RV-like particles (RVLPs) in vector-infected mammalian cells. Despite the observed splicing of VP6 RNA, full-length VP6 protein and RVLPs were efficiently produced. Intramuscular injection of mice with the amplicon vectors as a two-dose regimen without adjuvants resulted in RV-specific humoral immune responses and, most importantly, immunized mice were partially protected at the mucosal level from challenge with live wild-type (wt) RV. This work provides proof of principle for the application of HSV-1 amplicon vectors that mediate the efficient production of heterologous VLPs as genetic vaccines.

Statistics

Citations

Dimensions.ai Metrics
11 citations in Web of Science®
14 citations in Scopus®
13 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

2 downloads since deposited on 21 Sep 2012
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Institute of Veterinary Anatomy
05 Vetsuisse Faculty > Institute of Veterinary Pathology
05 Vetsuisse Faculty > Institute of Virology
Dewey Decimal Classification:570 Life sciences; biology
Language:English
Date:2012
Deposited On:21 Sep 2012 08:10
Last Modified:24 Sep 2018 08:03
Publisher:Nature Publishing Group
ISSN:1525-0016
OA Status:Closed
Publisher DOI:https://doi.org/10.1038/mt.2012.108
PubMed ID:22713696

Download